The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.0M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 695K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

14 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation.EBI
Institut Curie
Synthesis and evaluation of"AZT-HEPT","AZT-pyridinone", and"ddC-HEPT" conjugates as inhibitors of HIV reverse transcriptase.EBI
Institut Curie
3D-QSAR CoMFA on cyclin-dependent kinase inhibitors.EBI
Institut Curie
Novel 8-arylated purines as inhibitors of glycogen synthase kinase.EBI
Institut Curie
A Pd(0) based cross-coupling approach to the synthesis of 2-amidopurines and their evaluation as CDK inhibitors.EBI
Institut Curie
Synthesis and biological evaluation of novel flavone-8-acetic acid derivatives as reversible inhibitors of aminopeptidase N/CD13.EBI
Institut Curie
Synthesis of a molecular mimic of the Glc1Man9 oligoside as potential inhibitor of calnexin binding to DeltaF508 CFTR protein.EBI
Institut Curie
A new series of pyridinone derivatives as potent non-nucleoside human immunodeficiency virus type 1 specific reverse transcriptase inhibitors.EBI
Institut Curie
Indole carboxamide derivatives as P2X7 receptor antagonistsBDB
Actelion Pharmaceuticals
Heterocyclic compounds as PI3K-γ inhibitorsBDB
Incyte
Highly potent and selective ligands for a new class H3 of histamine receptor.BDB
UnitÉ
 
Potent, orally bioavailable HIV-1 protease inhibitors containing noncoded D-amino acidsBDB
Eli Lilly
Design and fast synthesis of C-terminal duplicated potent C(2)-symmetric P1/P1'-modified HIV-1 protease inhibitors.BDB
Uppsala University
Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes.BDB
The Johns Hopkins University